Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imsidolimab
- Development stage
- Phase 3
- Lead developer
- Vanda Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Imsidolimab is a high-affinity, fully humanized IgG4 monoclonal antibody that acts as an antagonist of the interleukin-36 receptor (IL-36R). By specifically binding to IL-36R, it blocks IL-36 signaling and thereby inhibits downstream proinflammatory pathways implicated in the pathogenesis of generalized pustular psoriasis (GPP) and other inflammatory diseases. Imsidolimab has demonstrated rapid onset of action and sustained efficacy in phase 2 and phase 3 clinical trials for GPP, with significant improvements in skin clearance and quality of life measures. The drug was originally developed by AnaptysBio, which has since entered into a global licensing agreement with Vanda Pharmaceuticals for its further development and commercialization[1][3][5][8].
- Other names
- imsidolimabANB 019ANB019ANB-019
02
Targets
IL1RL2 (Interleukin 36 Receptor)
Beyond the preview
Go deeper on imsidolimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imsidolimab.